As the pharmaceutical world gathers once again in Europe for CPHI Frankfurt 2025, we’re reminded of just how global—and interconnected—our industry truly is. Over three days this October, more than 62,000 pharma professionals and 2,000 exhibitors will converge to discuss the trends, technologies, and partnerships shaping the future of drug development and delivery.
For Contract Pharma, this issue is a chance to contribute to those conversations with timely coverage and analysis that cuts across science, manufacturing, and outsourcing strategy. In these pages, we’ve assembled a set of features that reflect the challenges and opportunities our readers face every day. Hamilton Lenox of LGM Pharma examines how to build resilience into API sourcing strategies amid geopolitical and regulatory volatility.
On the advanced therapy front, we explore how cell and gene therapies are reshaping supply chain expectations, with logistics evolving into a discipline as critical as science itself. We also talk about sustainability—from the global push to reformulate pMDIs with next-generation propellants to broader questions of how pharma can balance environmental stewardship with patient access and affordability.
This issue also marks an important transition for Contract Pharma. We are pleased to welcome Julie Fuhrer as our new Publisher. Julie brings more than two decades of experience in medical device media and marketing, making her an ideal fit to guide Contract Pharma into its next phase of growth. We extend our deepest thanks to Lauren Hanna, who has served with distinction as Publisher in recent years.
As you read this issue—whether in Frankfurt or elsewhere—I hope you find both insight and inspiration in its pages. The pharmaceutical outsourcing industry continues to evolve at an unprecedented pace, and our mission at Contract Pharma remains the same: to provide clarity, context, and a platform for the conversations that will shape tomorrow’s therapies.
Get started today with Solo access →
